Physician profile
Katherine E O'Brien
NPI 1033159124
$1,138.48
in general payments reported to CMS, 2019-2025
22 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $44.82 · 2021: $313 · 2022: $109 · 2023: $122 · 2024: $141 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.25 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2021 | |
| Exeltis, USA INC. | $161.25 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $114.97 | 2024-2025 | Veozah |
| Allergan, INC. | $86.46 | 2019-2020 | |
| Agile Therapeutics, INC. | $58.28 | 2022-2024 | Twirla |
| Coopersurgical, INC. | $54.85 | 2019-2025 | Sos |
| Hologic Sales and Service, LLC | $46.67 | 2019-2024 | Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $45.85 | 2022-2023 | |
| Millicent US INC | $45.80 | 2024-2025 | Femring, Intrarosa |
| Avion Pharmaceuticals | $35.22 | 2019-2021 | |
| Evofem Biosciences, INC. | $32.29 | 2023-2025 | Phexxi, Solosec, Phexx |
| Exact Sciences Corporation | $21.56 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $18.23 | 2025 | Gemtesa |
| Optumhealth Care Solutions, LLC | $17.71 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Mycovia Pharmaceuticals, INC. | $16.53 | 2023 | Vivjoa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $15.31 | 2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $14.79 | 2019 | |
| Duchesnay USA Incorporated | $14.00 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.00 | 2019 | |
| Therapeuticsmd, INC. | $12.82 | 2019 | |
| Abbvie INC. | $11.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine O'Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.